Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 45 for your search:
Start Over
Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix TM) Administered in Healthy Adolescents
Phase: Phase IV
Type: Prevention
Status: Completed
Age: 12 to 15
Sponsor: Pharmaceutical / Industry
Protocol IDs: 106636, 2007-001731-55, NCT00534638
Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects
Phase: Phase IV
Type: Natural history/Epidemiology
Status: Completed
Age: 20 to 60
Sponsor: Pharmaceutical / Industry
Protocol IDs: 112772, NCT00947115
Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Prevention
Status: Completed
Age: 13 to 15 at first immunization
Sponsor: Other
Protocol IDs: HPV CSP01, NCT00956553
Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Status: Completed
Age: 18 to 25
Sponsor: Pharmaceutical / Industry
Protocol IDs: CDR0000441189, NCI-04-C-N191, NCI-590299/009, GSK-590299/009, NCT00128661
Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Status: Completed
Age: 18 to 25
Sponsor: Pharmaceutical / Industry
Protocol IDs: 104772, NCT00250276
Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Status: Completed
Age: 26 and older
Sponsor: Pharmaceutical / Industry
Protocol IDs: 104820, NCT00294047
A Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Status: Completed
Age: 18 to 35
Sponsor: Pharmaceutical / Industry
Protocol IDs: 106001, NCT00306241
Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women
Phase: Phase III
Type: Natural history/Epidemiology, Prevention
Status: Completed
Age: 10 to 25
Sponsor: Pharmaceutical / Industry
Protocol IDs: 107476 (M18), 107477, 107479, 107481, NCT00337818
Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian Women
Phase: Phase III
Type: Prevention
Status: Completed
Age: 18 to 35
Sponsor: Pharmaceutical / Industry
Protocol IDs: 104479, NCT00344032
Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Status: Completed
Age: 18 to 35
Sponsor: Pharmaceutical / Industry
Protocol IDs: 105926, NCT00345878
Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine
Phase: Phase III
Type: Natural history/Epidemiology, Prevention
Status: Completed
Age: 10 to 14
Sponsor: Pharmaceutical / Industry
Protocol IDs: 104896 (month 18 FU), 104902, 104904, 104918, NCT00316706
Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects
Phase: Phase III
Type: Natural history/Epidemiology, Prevention
Status: Completed
Age: 11 to 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: 107682, NCT00369824
Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Status: Completed
Age: 18 to 45
Sponsor: Pharmaceutical / Industry
Protocol IDs: 108933, NCT00423046
Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects
Phase: Phase III
Type: Prevention
Status: Completed
Age: 10 to 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: 108464, NCT00426361
Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years
Phase: Phase III
Type: Prevention
Status: Completed
Age: 26 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 109801, NCT00456807
Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine 580299 in Healthy Females 10 - 25 Years of Age.
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Status: Completed
Age: 10 to 25
Sponsor: Pharmaceutical / Industry
Protocol IDs: 106069, NCT00481767
A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Status: Completed
Age: 15 to 25
Sponsor: Pharmaceutical / Industry
Protocol IDs: 107291, NCT00485732
Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Status: Completed
Age: 10 to 15
Sponsor: Pharmaceutical / Industry
Protocol IDs: 110168, NCT00492544
Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Status: Completed
Age: 15 to 25
Sponsor: Pharmaceutical / Industry
Protocol IDs: 109179, NCT00552279
Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects
Phase: Phase III
Type: Natural history/Epidemiology, Prevention
Status: Completed
Age: 9 to 15
Sponsor: Pharmaceutical / Industry
Protocol IDs: 110886, NCT00578227
Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)
Phase: Phase III
Type: Prevention
Status: Completed
Age: 20 to 25
Sponsor: Pharmaceutical / Industry
Protocol IDs: 111567, NCT00637195
Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Status: Completed
Age: 9 to 15
Sponsor: Pharmaceutical / Industry
Protocol IDs: 111507, NCT00652938
Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18
Phase: Phase III
Type: Prevention
Status: Completed
Age: 15 to 55
Sponsor: Pharmaceutical / Industry
Protocol IDs: 103514, 105879, 105880, 105881, 105882, NCT00196937
Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects
Phase: Phase III
Type: Prevention
Status: Closed
Age: 18 to 25
Sponsor: Pharmaceutical / Industry
Protocol IDs: 107638, NCT00779766
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Phase: Phase III
Type: Prevention
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 111955, NCT00799825
Start Over